Stenbolone acetate is a novel and potent anabolic steroid
| Targets |
Anabolic steroid
|
|---|---|
| ln Vitro |
The metabolism of stenbolone acetate (17 beta-acetoxy-2-methyl-5 alpha-androst-1-en-3-one), a synthetic anabolic steroid, has been studied in humans. Following oral administration of a single 50 mg dose to a male volunteer, nine metabolites were detected in urine, either as glucuronic or sulfuric acid conjugates. The parent compound, stenbolone, was detectable for over 120 hours post-administration, with cumulative excretion accounting for 6.6% of the ingested dose. Most metabolites of stenbolone acetate were isolated from the glucuronic acid fraction, including: stenbolone, 3 alpha-hydroxy-2-methyl-5 alpha-androst-1-en-17-one, 3 alpha-hydroxy-2 xi-methyl-5 alpha-androst-17-one; three isomers of 3 xi, 16 xi-dihydroxy-2-methyl-5 alpha-androst-1-en-17-one; 16 alpha and 16 beta-hydroxy-2-methyl-5 alpha-androst-1-ene-3, 17-dione; and 16 xi, 17 beta-dihydroxy-2-methyl-5 alpha-androst-1-en-3-one. Only isomeric metabolites containing a 16 alpha or 16 beta-hydroxyl group were detected in the sulfate fraction. Notably, no metabolites were found in the unconjugated steroid fraction. The identities of the steroids were determined through analysis of their TMS ether, TMS enol-TMS ether, MO-TMS, and d9-TMS ether derivatives, as well as by comparison with reference compounds and structurally related steroids. The data indicate that stenbolone acetate undergoes metabolism into several compounds resulting from oxidation of the 17 beta-hydroxyl group and/or reduction of the A-ring delta-1 and/or 3-keto functions, with or without hydroxylation at the C16 position. Finally, a comparison of the urinary metabolites of stenbolone acetate with those of methenolone acetate reveals similar biotransformation pathways for these delta-1-3-keto anabolic steroids. This suggests that the position of the methyl group at the C1 or C2 position in these steroids has minimal impact on their major biotransformation routes in humans, with the exception that stenbolone cannot produce metabolites with a 2-methylene group, as its 2-methyl group cannot isomerize into a 2-methylene function through enolization of the 3-keto group, a process previously observed for methenolone.
|
| References |
[1]. Studies on anabolic steroids--6. Identification of urinary metabolites of stenbolone acetate (17 beta-acetoxy-2-methyl-5 alpha-androst-1-en-3-one) in human by gas chromatography/mass spectrometry. J Steroid Biochem Mol Biol. 1991 May;38(5):639-55.
|
| Additional Infomation |
Stenbolone is a 3-hydroxy steroid. It has a role as an androgen.
stenbolone is a DEA Schedule III controlled substance. Substances in the DEA Schedule III have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence. It is a Anabolic steroids substance.
structure given in first source; RN given from Merck; RN given refers to the (5alpha,17beta)-isomer; RN for cpd without isomeric designation not available 7/91
|
| Molecular Formula |
C22H32O3
|
|---|---|
| Molecular Weight |
344.49
|
| Exact Mass |
344.235
|
| CAS # |
1242-56-4
|
| Related CAS # |
5197-58-0
|
| PubChem CID |
10315500
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.696
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
635
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(OC1CCC2C3CCC4CC(C(=CC4(C)C3CCC12C)C)=O)=O
|
| InChi Key |
FYTLCZSXKONUTF-OIELIUQCSA-N
|
| InChi Code |
InChI=1S/C22H32O3/c1-13-12-22(4)15(11-19(13)24)5-6-16-17-7-8-20(25-14(2)23)21(17,3)10-9-18(16)22/h12,15-18,20H,5-11H2,1-4H3/t15-,16-,17-,18-,20-,21-,22-/m0/s1
|
| Chemical Name |
[(5S,8R,9S,10S,13S,14S,17S)-2,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate
|
| Synonyms |
S-3760; S 3760; STENBOLONE ACETATE; 1242-56-4; 36HF75V9XI; DTXSID40924751; RefChem:185541; Stenbolone acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9028 mL | 14.5142 mL | 29.0284 mL | |
| 5 mM | 0.5806 mL | 2.9028 mL | 5.8057 mL | |
| 10 mM | 0.2903 mL | 1.4514 mL | 2.9028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
